Medix Biochemica
Medix Biochemica, a leading provider of high-quality raw materials for the in vitro diagnostics (IVD) industry, is headquartered in Finland (FI). Founded in 1985, the company has established a strong presence in key operational regions, including Europe, North America, and Asia. Medix Biochemica specialises in the development and manufacturing of antigens, antibodies, and other critical components for diagnostic tests, setting itself apart with its commitment to innovation and quality. With a focus on enhancing diagnostic accuracy, Medix Biochemica has achieved significant milestones, including ISO certifications and partnerships with major diagnostic companies. The firm is recognised for its extensive product portfolio, which supports a wide range of applications in clinical laboratories. As a trusted name in the IVD sector, Medix Biochemica continues to drive advancements in diagnostics, solidifying its market position through excellence and reliability.
DitchCarbon Score
How does Medix Biochemica's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medix Biochemica's score of 29 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medix Biochemica's reported carbon emissions
In 2023, Medix Biochemica reported total carbon emissions of approximately 9,200,000 kg CO2e. This figure includes 4,492,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources. Scope 2 emissions, related to the generation of purchased electricity, steam, heating, and cooling, amounted to about 2,535,000 kg CO2e. Additionally, Scope 3 emissions, which cover indirect emissions from the value chain, totalled approximately 1,945,000 kg CO2e, with purchased goods and services contributing around 2,268,000 kg CO2e. Currently, Medix Biochemica has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s commitment to addressing climate change remains evident, but further details on their strategies for emissions reduction are not available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 4,492,000 |
| Scope 2 | 2,535,000 |
| Scope 3 | 1,945,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medix Biochemica is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
